Neurosterix raised a $105 million Series B to advance a lead schizophrenia candidate targeting one of Bristol Myers Squibb’s drug targets. The funding round also reassembles key figures tied to Cobenfy, positioning the company to continue clinical progress while building momentum in a crowded CNS market. The financing underscores how investors are still underwriting mechanism-driven psychiatry programs, especially those connected to validated therapeutic targets.